Literature DB >> 10657955

Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol.

L W Wattenberg1, T S Wiedmann, R D Estensen, C L Zimmerman, A R Galbraith, V E Steele, G J Kelloff.   

Abstract

This investigation is part of an effort to develop chemoprevention for carcinogenesis of the lung. It focuses on the efficacy of low doses of synthetic glucocorticoids administered either as single agents or in combination with a second compound, myo-inositol. Glucocorticoids are potent inhibitors of carcinogenesis. The use of low doses is important to avoid potential side-effects. The synthetic glucocorticoid budesonide, administered by aerosol for 20 s three times a week, was studied to determine its effects on benzo[a]pyrene-induced pulmonary adenoma formation in female A/J mice. Two dose levels were employed, 10 and 25 microg/kg body wt. The lower dose produced a 34% reduction in lung tumor formation and the higher dose level a 60% reduction in lung tumors. In additional groups of mice, the effects of 0.3% myo-inositol added to the diet was found to reduce pulmonary tumor formation by 53%. The two agents given in combination resulted in a greater inhibition of lung tumor formation than either by itself. Budesonide at 10 microg/kg body wt plus 0.3% myo-inositol reduced the number of tumors by 60% and budesonide at 25 microg/kg body wt plus 0.3% myo-inositol reduced lung tumor formation by 79%. To determine whether a glucocorticoid other than budesonide would have inhibitory effects in this experimental model, beclomethasone dipropionate administered by aerosol for 20 s three times a week was studied as a single agent and showed almost identical inhibitory properties to budesonide. The doses of the glucocorticoids calculated on a daily basis are within the range of those used widely for control of chronic allergic respiratory diseases in the human. The capacity of low doses of inhaled glucocorticoids to prevent pulmonary neoplasia and the enhancement of this preventive effect by myo-inositol, an essentially non-toxic compound, are findings that should encourage further work to evaluate the applicability of these agents to the prevention of neoplasia of the lung in the human.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657955     DOI: 10.1093/carcin/21.2.179

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  27 in total

1.  Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.

Authors:  Michael A Pereira; Blake M Warner; Thomas J Knobloch; Christopher M Weghorst; Ronald A Lubet; Vernon E Steele; Bruce C Casto
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

Review 2.  Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

Authors:  Silvio De Flora; Gancho Ganchev; Marietta Iltcheva; Sebastiano La Maestra; Rosanna T Micale; Vernon E Steele; Roumen Balansky
Journal:  Trends Pharmacol Sci       Date:  2015-12-23       Impact factor: 14.819

3.  Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.

Authors:  Bilal Bin Hafeez; Joseph W Fischer; Ashok Singh; Weixiong Zhong; Ala Mustafa; Louise Meske; Mohammad Ozair Sheikhani; Ajit Kumar Verma
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-27

4.  Applicability of an ultrasonic nebulization system for the airways delivery of beclomethasone dipropionate in a murine model of asthma.

Authors:  Boska Hrvacić; Berislav Bosnjak; Marijan Tudja; Milan Mesić; Mladen Merćep
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

5.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

6.  Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung.

Authors:  Alberto Izzotti; Patrizia Larghero; Cristina Cartiglia; Mariagrazia Longobardi; Ulrich Pfeffer; Vernon E Steele; Silvio De Flora
Journal:  Carcinogenesis       Date:  2010-02-09       Impact factor: 4.944

7.  Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers.

Authors:  Bilal Bin Hafeez; Weixiong Zhong; Ala Mustafa; Joseph W Fischer; Olya Witkowsky; Ajit K Verma
Journal:  Carcinogenesis       Date:  2012-09-13       Impact factor: 4.944

Review 8.  The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Authors:  Robert H Shoemaker; Chen S Suen; Cathy A Holmes; Judith R Fay; Vernon E Steele
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

9.  Relationships between pulmonary micro-RNA and proteome profiles, systemic cytogenetic damage and lung tumors in cigarette smoke-exposed mice treated with chemopreventive agents.

Authors:  Alberto Izzotti; Roumen Balansky; Francesco D'Agostini; Mariagrazia Longobardi; Cristina Cartiglia; Sebastiano La Maestra; Rosanna T Micale; Anna Camoirano; Gancho Ganchev; Marietta Iltcheva; Vernon E Steele; Silvio De Flora
Journal:  Carcinogenesis       Date:  2013-05-24       Impact factor: 4.944

Review 10.  Lung cancer chemoprevention: current status and future prospects.

Authors:  Robert L Keith; York E Miller
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.